Early evidence suggests safety, efficacy, while awaiting data on durability in broader pop ...
AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...
CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in modern medicine. Equipping T cells, a key cell type of the immune system, ...
Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.
Researchers at the University of Chicago have developed a "universal" chimeric antigen receptor (CAR) platform that offers enhanced safety, adaptability, and the potential to overcome long-standing ...
A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...
In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...
Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Since their launch in 2017, chimeric antigen receptor T-cell therapies ...
In a clinical trial of 7 patients, anti-BCMA only CAR-T cell treated patients with refractory lupus nephritis safely and effectively. Anti-B cell maturation antigen (BCMA)-targeting chimeric antigen ...